Novartis Sends Clozaril “Dear Doctor” Letter On Antipsychotic Class Diabetes Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Although similar information was previously included in the “Precautions” section of Clozaril labeling, “Novartis concurs with the FDA that the safe use of atypical antipsychotics can be enhanced” by referencing diabetes adverse events in the “Warnings” section, the letter states.